scholarly journals Locoregional immunotherapy in cancer patients: Review of clinical studies

2000 ◽  
Vol 11 (10) ◽  
pp. 1229-1240 ◽  
Author(s):  
C.M.L. van Herpen ◽  
P.H.M. De Mulder
Keyword(s):  
Cancer Patients ◽  
Clinical Studies

Weekly Low Dose Epirubicin in Elderly Cancer Patients

1996 ◽  
Vol 82 (4) ◽  
pp. 369-371 ◽  
Author(s):  
Dario Nicolella ◽  
Giuseppe Grimaldi ◽  
Giuseppe Colantuoni ◽  
Mario Belli ◽  
Giuseppe Frasci ◽  
...  
Keyword(s):  
Side Effects ◽  
Elderly Patients ◽  
Cancer Patients ◽  
Combination Chemotherapy ◽  
Clinical Studies ◽  
Low Dose ◽  
Performance Status ◽  
Elderly Cancer Patients ◽  
Grade 3 ◽  
Severe Mucositis

Aims and background The treatment of elderly patients with metastatic solid tumours is still a debated problem. Patients over 75 years are generally excluded from combination chemotherapy trials because of higher toxicity. Several clinical studies have shown that weekly low dose epirubicin is a well tolerated and effective treatment for elderly cancer patients (breast, prostate, lung). Methods We report a study of patients aged between 75 and 85 years affected by metastatic anthracyclines-sensible carcinomas, to assess the tolerance of epirubicin given weekly at a dose of 25 mg/m2. Results 25 patients (13 males, 12 females; ECOG P.S. 0-2) entered the study and were evaluable for side effects. One-hundred and ninety-six cycles of therapy have been administered. Side effects were never severe. Mucositis (9 patients), leucopenia (7 patients), anemia (5 patients) were usually of grade 1 or 2. Grade 1 cardiotoxicity (tachycardia) was observed in only one case. Grade 3 toxicity consisted in anemia (1 patient) and mucositis (1 patient), while grade 4 toxicity never occurred. Nineteen patients were evaluable for response: 0 CR, 4 PR (1 lung, 3 breast), 8 SD (3 lung, 3 breast, 2 prostate) have been observed. Compliance was encouraging and the majority of patients showed a decrease in symptoms and an improvement in performance status. Conclusions Weekly low-dose epirubicin is a very well tolerated treatment in elderly cancer patients. In view of the negligible toxicity encountered, it could be of utility to test this regimen in patients aged 75 years or older, affected by anthracyclines-sensible metastatic tumors, also to assess activity.

Thrombus and thrombosis in cancer patients with permanent venous catheters

2000 ◽  
Vol 20 (03) ◽  
pp. 143-145
Author(s):  
H. D. Bruhn ◽  
F. Gieseler
Keyword(s):  
Risk Factors ◽  
Cancer Patients ◽  
Clinical Studies ◽  
Central Venous Catheters ◽  
Central Venous ◽  
Vascular Lumen ◽  
Additive Risk ◽  
Thrombotic Complications ◽  
Port Systems ◽  
Central Catheters

SummaryCancer patients have additive risk factors for thrombosis especially if permanent central catheters (port systems) are used for the delivery of chemotherapy. In our hospital the rate of thrombotic complications is below 5% for cancer patients receiving chemotherapy via port systems. This is in contrast to clinical studies, which have shown that up to 60% of catheters acquire clots that obstruct more than 50% of the vascular lumen. It is reasonable to believe that complications arising from thrombotic catheter alterations, such as bacterial hosting or micro-emboli, are clinically underestimated. The identification of thrombotic alterations of permanent central venous catheters in cancer patients receiving chemotherapy is substantial for the estimation whether anticoagulation strategies should be used as prophylaxis.

A survey of breast cancer patients' views on entry into several clinical studies

2004 ◽  
Vol 13 (1) ◽  
pp. 32-35 ◽  
Author(s):  
K. BURNET ◽  
J. BENSON ◽  
H. EARL ◽  
H. THORNTON ◽  
K. COX ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Studies ◽  
Breast Cancer Patients

Systematic approach for development of new immunotherapeutics for lung cancers through cancer genomics analysis.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3092-3092
Author(s):  
Yataro Daigo ◽  
Atsushi Takano ◽  
Yusuke Nakamura
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Clinical Studies ◽  
Critical Role ◽  
Phase I Clinical Trials ◽  
Lung Cancers ◽  
Lung Cancer Patients ◽  
High Immunogenicity

3092 Background: Oncoantigens are defined to be proteins that are very specifically expressed in cancer cells and that have the oncogenic activity and high immunogenicity, and are considered to be promising targets for immunotherapy such as therapeutic cancer vaccines. Methods: We have established a strategy as follows to identify new oncoantigens; i) screening of highly transactivated genes in the majority of 120 lung cancers using cDNA microarray representing 27,648 genes coupled with enrichment of tumor cells by laser microdissection, ii) verification of no expression of each candidate gene in normal tissues by northern-blot analysis, iii) validation of the clinicopathological significance of its high level of expression with tissue microarray containing 300 lung cancers, iv) verification of a critical role of each gene in the growth or invasiveness of cancer cells by RNAi and cell growth/invasion assays, v) screening of the epitope peptides recognized by HLA-A*0201- or A*2402-restricted cytotoxic T lymphocyte (CTL). We conducted phase I clinical trials of these therapeutic peptide vaccines for lung cancer patients. Results: We identified 35 oncoantigens and screened dozens of 10-amino-acid peptides, each of which corresponded to a part of TTK, LY6K, IMP-3, CDCA1, KIF20A, CDC45L, and FOXM1, and was a candidate to be presented on the surface of HLA-A*0201 or HLA-A*2402 that induced in vitro CTL response. Phase I clinical studies indicated that five epitope peptides could strongly induce the CTL activity in cancer patients. For example, we conducted a phase I study for HLA-A*2402-positive, advanced non-small cell lung cancer patients who failed to standard therapy, using the combination of 1, 2 or 3 mg/body of each peptides from LY6K, CDCA1, and KIF20A mixed with adjuvant once a week. This cancer vaccine therapy demonstrated tolerability and had very high immunogenicity of even 1 mg/body dose to induce antigen-specific CTLs in cancer patients. Conclusions: Through systematic genomics-based approach and clinical study, we have identified five epitope peptides, which could induce CTLs very effectively in cancer patients, and therefore it warrants further clinical studies. Clinical trial information: NCT01069575.

scholarly journals Therapeutic Applications of Herbal Medicines for Cancer Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-15 ◽  
Author(s):  
Shu-Yi Yin ◽  
Wen-Chi Wei ◽  
Feng-Yin Jian ◽  
Ning-Sun Yang
Keyword(s):  
Cancer Patients ◽  
Clinical Studies ◽  
Immune Modulation ◽  
Herbal Medicines ◽  
Research Area ◽  
Cellular Mechanisms ◽  
Technological Support ◽  
Beneficial Effects ◽  
Tumor Microenvironments ◽  
Specific Tumor

Medicinal herbs and their derivative phytocompounds are being increasingly recognized as useful complementary treatments for cancer. A large volume of clinical studies have reported the beneficial effects of herbal medicines on the survival, immune modulation, and quality of life (QOL) of cancer patients, when these herbal medicines are used in combination with conventional therapeutics. Here, we briefly review some examples of clinical studies that investigated the use of herbal medicines for various cancers and the development of randomized controlled trials (RCTs) in this emerging research area. In addition, we also report recent studies on the biochemical and cellular mechanisms of herbal medicines in specific tumor microenvironments and the potential application of specific phytochemicals in cell-based cancer vaccine systems. This review should provide useful technological support for evidence-based application of herbal medicines in cancer therapy.

Clinical studies of p53 in treatment and benefit of breast cancer patients.

1999 ◽  
pp. 51-59 ◽  
Author(s):  
J Bergh
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Predictive Factor ◽  
Clinical Studies ◽  
Review Article ◽  
Breast Cancer Patients ◽  
National Library ◽  
Specific Therapy ◽  
P53 Status

This article describes p53 as a prognostic and predictive factor, together with some information on how best to determine the p53 status. By December 1998, 13,000 articles on p53 were identified on Pub Med, the National Library of Medicine. Within one week a further 62 articles were recorded making it difficult to give the complete p53 story. This review article will focus on discussing p53 in relation to its predictive potential. So far, no firm conclusions can be made based on the articles studied. This may be, in part, because many studies have used less than optimal techniques for determination of the p53 status, together with the fact that the studies lacked power to detect a potential difference in outcome from specific therapy in relation to p53 status.

scholarly journals Clinical studies on the serum levels of immunosuppressive acidic protein (IAP) of oral cancer patients

1980 ◽  
Vol 26 (6) ◽  
pp. 1415-1421 ◽  
Author(s):  
Motohiro WATANABE ◽  
Masashi NUMATA ◽  
Naoya TASHIRO ◽  
SUSUMU HAYASHI ◽  
Keiji TAMURA ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Cancer Patients ◽  
Clinical Studies ◽  
Serum Levels ◽  
Acidic Protein ◽  
Immunosuppressive Acidic Protein ◽  
Oral Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document